Work

Myeloma developing regimens using genomics (MyDRUG) trial: Results from the RAS mutation targeting arm.

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.8055

Authors: Shaji Kumar, Giada Bianchi, Noa Biran, Malin Hultcrantz, Joshua Ryan Richter, Ravi Vij, Jing Christine Ye, Jeffrey A. Zonder, Lauren DiLello, Jen Yesil, Hearn J. Cho

Institutions: Mayo Clinic, Harvard University, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, Hackensack University Medical Center, Memorial Sloan Kettering Cancer Center, Washington University in St. Louis, The Barbara Ann Karmanos Cancer Institute, Wayne State University, Multiple Myeloma Research Foundation, Icahn School of Medicine at Mount Sinai

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Multiple Myeloma Research Foundation

OpenAlex ID: W4286296009

Cites:

Cited by: 9

Related to: 10